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Leishmania major causes leishmaniasis and is grouped within the Trypanosomatidae family, which also includes the etiologic
agent for African sleeping sickness, Trypanosoma brucei. Previous studies on T. brucei showed that acyl carrier protein (ACP)
of mitochondrial fatty acid synthase type 2 (FASII) plays a crucial role in parasite survival. Additionally, 3-oxoacyl-ACP
synthase TbKASIII as well as TbHTD2 representing 3-hydroxyacyl-ACP dehydratase were also identiﬁed; however, 3-oxoacyl-ACP
reductase TbKAR1 has hitherto evaded positive identiﬁcation. Here, potential Leishmania FASII components LmjF07.0440 and
LmjF07.0430 were revealed as 3-hydroxyacyl-ACP dehydratases LmHTD2-1 and LmHTD2-2, respectively, whereas LmjF27.2440
was identiﬁed as LmKAR1. These Leishmania proteins were ectopically expressed in Saccharomyces cerevisiae htd2Δ or oar1Δ
respiratory deﬁcient cells lacking the corresponding mitochondrial FASII enzymes Htd2p and Oar1p. Yeast mutants producing
mitochondrially targeted versions of the parasite proteins resembled the self-complemented cells for respiratory growth. This is
the ﬁrst identiﬁcation of a FASII-like 3-oxoacyl-ACP reductase from a kinetoplastid parasite.
Copyright © 2009 Aner Gurvitz.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Leishmania species represent a group of parasitic proto-
zoa that cause widespread morbidity and even mortal-
ity (http://www.who.int/tdr/diseases/leish/diseaseinfo.htm),
which are transmitted to humans through the bites of
sandﬂies (for reviews on visceral, cutaneous, and mucosal
leishmaniases, see [1, 2]). Leishmania spp. are clustered
within the Trypanosomatidae family that additionally con-
tains Trypanosoma spp. and Crithidia fasciculata. The World
Health Organisation estimates that approximately 12 million
people suﬀer from various forms of leishmaniasis, some
of which are lethal if left untreated. It is estimated that
about 350 million people are at risk worldwide, and
human infections are found in 16 countries in Europe
(http://www.who.int/tdrold/diseases/leish/ﬁles/leish-poster.
pdf). As a genus, Leishmania represents a major global
human disease agent. Apparently, there is a rise in the rate of
new Leishmania infections, and Leishmania/HIV coinfection
has been termed as an emerging disease in southern Europe.
Moreover, drug resistance has also been reported recently.
Since most available drugs are expensive, and treatment is
long and accompanied by severe side eﬀects but at the same
time becoming less eﬀective, there is a renewed interest and
urgency in developing new antileishmanial drugs.
An attractive target process for novel drug design is
represented by the type 2 fatty acid synthase (FASII) system
[3, 4], which occurs in the mitochondria of trypanoso-
matids [5]. Despite the fact that the L. major genome
was completely sequenced in 2005 [6], there is currently
no information available on mitochondrial FASII in this
particular kinetoplastid parasite. Pioneering studies on T.
brucei revealed that it has an essential mitochondrial FASII
process, which it employs for the production of octanoate
and palmitate [7]. It was found that RNAi depletion of
the mitochondrial acyl carrier protein (ACP) signiﬁcantly
reduced cytochrome-mediated respiration in the procyclic
form of trypanosomes, and eﬀected changes in mitochon-
drial morphology and alterations in the membrane potential
[7, 8]. In addition to ACP, the T. brucei FASII enzymes2 Journal of Biomedicine and Biotechnology
Table 1: Plasmids and oligonucleotides used.
Plasmids or oligonucleotides Description Sources or references
plasmida
1] pBluescript II KS pKS cloning vector Stratagene
pKS:LmjF07.04401 LmjF07.0440 in pBluescript (with primers for LmHTD2-1) This study
pKS:LmjF07.04301 LmjF07.0430 in pBluescript (with primers for LmHTD2-2) This study
pKS:LmjF27.24401 LmjF27.2440 in pBluescript (with primers for LmOAR1-1) This study
pKS:LmjF24.20301 LmjF24.2030 in pBluescript (with primers for LmOAR1-2) This study
2] YEp352 URA3-marked multicopy plasmid [17]
3] YEp:CTA12 CTA1 behind its promoter (pYE352:CTA1)[ 18]
YEp:LmjF07.04403 LmjF07.0440 behind the CTA1 promoter This study
YEp:LmjF07.04303 LmjF07.0430 behind the CTA1 promoter This study
YEp:LmjF27.24403 LmjF27.2440 behind the CTA1 promoter This study
YEp:LmjF24.20303 LmjF24.2030 behind the CTA1 promoter This study
YEp:OAR13 OAR1 behind the CTA1 promoter [14]
YEp:YHR067w3 HTD2 behind the CTA1 promoter [12]
oligonucleotideb
Lm HTD2-1 5  NcoI TTATCCATGGAAGCGGCAGCACGCCGCATCATC This study
Lm HTD2-1 3  HindIII TATTAAGCTTAAAGCCGACGCTCCACTCGCTC This study
Lm HTD2-2 5  NcoI TTATCCATGGCCAGCGAGACTGCACCACTTGTC This study
Lm HTD2-2 3  HindIII TATTAAGCTTACTTCGTCACAGACCACTCACTC This study
Lm OAR1-1 5  NcoI TTATCCATGGGTGCCCCTAACGCACACCCAC This study
Lm OAR1-1 3  HindIII TATTAAGCTTACGATAAGCCGCCATCGACGGCG This study
Lm OAR1-2 5  NcoI TTATCCATGGACGCCAAGTCCATCCAGTCG This study
Lm OAR1-2 3  HindIII TATTAAGCTTACTTGGCTGCCATACGGGTTGCC This study
aThe numbers in superscript following the plasmids’ designation refer to their parental vectors, for example, pKS:LmjF07.04401 was derived from 1]
pBluescript II KS.
bLm HTD2-1 refers to LmjF07.0440, Lm HTD2-2 to LmjF07.0430, Lm OAR1-1 to LmjF27.2440, and Lm OAR1-2 to LmjF24.2030.
3-oxoacyl-ACP synthase KASIII [7] and 3-hydroxyacyl-
ACP dehydratase HTD2 [9] have also been identiﬁed.
Furthermore, mitochondrial compartmentalisation of three
FabG candidates of T. brucei FASII, annotated as KAR1,
KAR2,andKAR3,hasbeenconvincinglydemonstratedusing
fusions with green ﬂuorescent protein GFP [7]; however,
their physiological function as 3-oxoacyl-ACP reductases of
mitochondrial FASII has hitherto not been reported. Thus, it
is important to identify Leishmania KAR1 so as to complete
our picture of mitochondrial FASII in trypanosomatids, and
in doing so to gain a better understanding of the enzymes
undertaking this process, thereby reﬁning our appreciation
of their potential suitability for novel drug design.
A convenient and safe method for revealing the identity
of parasite proteins is to demonstrate their physiological
function in Saccharomyces cerevisiae mutant cells missing
the corresponding yeast enzymes. In fungi, FASII is a mito-
chondrial process that is critical for organellar function and
morphology, and a lesion in any one of the genes encoding
FASII proteins results in a respiratory growth phenotype,
underdeveloped mitochondria lacking cytochromes, and,
in some cases, loss of mitochondrial DNA (reviewed in
[10, 11]). For instance, yeast htd2Δ mutants devoid of
the mitochondrial FASII enzyme 3-hydroxyacyl-ACP dehy-
dratase Htd2p [12] were used previously to identify T. brucei
HTD2 [9]. Another more recent example of how yeast FASII
mutants were employed as a surrogate host for functional
complementation studies is represented by the manner in
which oar1Δ mutant cells lacking the mitochondrial 3-
oxoacyl-ACPreductaseOar1p[13]hadhelpedtoidentifythe
human and nematode counterpart reductases [14, 15].
Here, S. cerevisiae was exploited further as a heterol-
ogous system for determining whether candidate L. major
HTD2 and KAR1 proteins might represent physiologically
functional FASII enzymes. This was done by monitoring the
potential interchangeability of ectopically expressed Leish-
mania proteins that were preceded by a mitochondrial leader
sequence (MLS) with the analogous fungal enzymes Htd2p
or Oar1p in the aforementioned respiratory deﬁcient strains
(htd2Δ and oar1Δ mutant cells) during growth on glycerol
medium. The results are viewed from the perspective of
the utility of yeast FASII mutants for identifying Leishmania
FASII enzymes.
2.MaterialsandMethods
2.1.S.cerevisiaeStrains,Plasmids,andOligonucleotides. Plas-
mids and oligonucleotides used are catalogued in Table 1.
The Escherichia coli strain TOP10 F  (Invitrogen, Carlsbad,
CA, USA) was exploited for all plasmid multiplicationsJournal of Biomedicine and Biotechnology 3
LmjF07.0440:
LmjF07.0430:
TbHTD2       : : 75 
LmjF07.0440: : 71 
LmjF07.0430: : 72 
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LmjF07.0430: : 146 
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LmjF07.0430:
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Figure 1: Similarity of L. major LmjF07.0440 and LmjF07.0430 to their T. brucei homologue, TbHTD2. Explanations for this and Figure 3
are given. Multalin- and Genedoc-based comparison of the deduced amino acid sequences is provided. Dashes indicate the arrangement of
the sequences for best ﬁt. Black shadings refer to conserved amino acid residues among all three sequences whereas the darker and lighter
grey shadings denote regions with more relaxed residue similarities not necessarily shared by the full set of sequences. MitoProt predictions
of cleaved mitochondrial leader sequences are indicated (+). Active site residues of human mitochondrial dehydratase D62 and H67 are
denoted (), whereas the hydratase 2 domain is underscored (∗). The sequences used for the Leishmania proteins throughout this work
were retrieved from GeneDB of the Sanger Institute, whereas the accession number for TbHTD2 was Q580H9 9TRYP.
and puriﬁcations. The mutant yeast strains BY4741oar1Δ
(MATa his3Δ1l e u 2 Δ0m e t 1 5 Δ0u r a 3 Δ0 ykl055c::kanMX)
and BY4741htd2Δ (yhr067w::kanMX)w e r ea c q u i r e df r o m
EUROSCARF (http://www.uni-frankfurt.de/). Expression
plasmids were incorporated into yeast cells using a reported
procedure [16], and transformants were kept on SD-Ura
medium, outlined below.
2.2. Plasmid Constructions. DNA inserts were assembled
within plasmids according to standard methods [19]. The
LmjF07.0430, LmjF07.0440, LmjF27.2440, and LmjF24.2030
genes were ampliﬁed from genomic L. major DNA by
polymerase chain reaction (PCR) and the corresponding
oligonucleotide pairs (Table 1). Sequential electrophoresis,
processing, and tethering of amplicons to an EcoRV-digested
pBluescript II plasmid vector (Stratagene, La Jolla, CA) are
described [20]. The inserts were puriﬁed following digestion
of the recombinant pBluescript plasmids with NcoIa n d
HindIII restriction enzymes and ﬁtted within a previously
published plasmid YEp352:CTA1 [18] that is based on a
URA3-marked YEp352 multicopy vector [17]. These inserts
were placed behind the CTA1 promoter as gene fusions
with the nucleotides for a cleavable N-terminal yeast MLS
directing Coq3p to the organelle [21], as described in [20].
NucleotidesequencingofthepBluescriptinsertsensuredthat
no mutations were introduced during the PCR ampliﬁcation
step. In addition, this procedure was also applied to the
YEp352-based expression plasmids, verifying that the read-
ing frame across the fusion boundary between the L. major
genesandtheyeastCOQ3nucleotidesencodingtheMLSwas
intact. Plasmid YEp352:OAR1 expressing yeast OAR1 as well
as plasmid YEp352:YHR067w producing fungal Hdt2p are
both described [12, 14].
2.3. Media, Enzyme Assays, Respiration Competence, and
Lipoic Acid Measurements. Standard media were made for
yeast[22]andE.coli[23].URA3-markedmulticopyplasmids
were kept in transformed S. cerevisiae strains by bearing
upon the cells selective pressure using solid SD-Ura medium.
Thismediumconsistedof0.67%(wt/vol)yeastnitrogenbase
without amino acids, 2% (wt/vol) D-glucose, 3% (wt/vol)
agar, and with all necessary supplements added with the
exceptionofuracil(Sigma-AldrichInc.,St.Louis,MO,USA).
Solid synthetic complete glycerol medium (SCglycerol) was
processed essentially as the previous SD-Ura medium,
with the only two diﬀerences being the addition of uracil
and replacement of glucose with 3% (wt/vol) glycerol as
the exclusive carbon source. Respiration competence was
tested using an overlay made with 0.1% (wt/vol) 2,3,5-
triphenyltetrazolium chloride, (TTC) [24]. Lipoic acid was
determined using a biological method that followed the
growth of a lipoic acid-deﬁcient E. coli strain in response to
thepresenceoflipoicacidinyeastcells,witheachyeaststrain
being propagated in triplicate cultures [25, 26].
2.4. Mitochondrial Localisation Predictions and Sequence
Comparisons. MitoProt (http://ihg2.helmholtz-muenchen.
de/ihg/mitoprot.html), PSORT II (http://psort.ims.u-
tokyo.ac.jp/form2.html), and TargetP (http://cbs.dtu.dk/
services/TargetP/) were used to identify N-terminal mito-
chondrial targeting sequences [27, 28]. Multalin
(npsa-pbil.ibcp.fr/cgi-bin/npsa automat.pl?page=/NPSA/
npsa multalin.html) and Genedoc (http://www.nrbsc.org/
gfx/genedoc/index.html) were used to compare the
sequences in Figures 1 and 3.
3. Results
3.1. LmjF07.440 and LmjF07.430 Are Functional 3-hydroxy-
acyl-ACP Dehydratases in Yeast. The L. major database
(http://www.genedb.org/) contains two sequences with a
high degree of similarity to T. brucei HTD2
(Q580H9 9TRYP) representing mitochondrial 3-hydroxy-
acyl-ACP dehydratase (Figure 1). Both LmjF07.0440 and4 Journal of Biomedicine and Biotechnology
LmjF07.0430 are annotated in this database as maoc
family dehydratase-like proteins with very high probability
values for being identical to TbHTD2 (BlastP E-scores
1.6e-30 and 5.0e-29, resp.). To predict whether the two
Leishmania proteins might reside in mitochondria, three
separate algorithms were used to analyze their deduced
amino acid sequences: MitoProt (MP), PSORT II (PS), and
TargetP (TP). The probability (in brackets) that each of
the Leishmania proteins would represent a mitochondrial
enzyme was calculated and compared to the values obtained
for TbHTD2: LmjF07.0440 (MP, 0.9974; PS, 78.3%; TP,
0.739), LmjF07.0430 (0.7896; 30.4%; 0.577), and TbHTD2
(0.8086, 43.5%, 0.699). In addition, both Leishmania
proteins also contained the hydratase 2 motif [29]a sw e l la s
amino acids germane with the active site residues of human
mitochondrial dehydratase [30]. Hence, LmjF07.0440 and
LmjF07.0430 were promising HTD2 candidates.
To investigate whether LmjF07.0440 and LmjF07.0430
might function as 3-hydroxyacyl-ACP dehydratases, their
respective genes were expressed from the promoter of the
yeast CTA1 gene for peroxisomal catalase A (Cta1p), which
is only slightly derepressed under the glycerol medium
conditions used here [31, 32]. Due to the lowered PS
values for LmjF07.0430 compartmentalisation (compared
to LmjF07.0440 and TbHTD2), a fungal MLS was fused
to the two Leishmania proteins. Yeast htd2Δ mutant cells
were transformed with plasmids for expressing native
Htd2p (positive control), Cta1p (negative control), or the
mitochondrially targeted Leishmania proteins LmjF07.0440
and LmjF07.0430. Transformants were grown on SD-Ura
medium, and after successively diluting the yeast cells by a
factor of ten, a volume of 2.5μL of the dilutions was applied
to SD-Ura or SCglycerol media, and the plates were kept at
30◦C until single colonies were discernible. The results in
Figure 2 revealed that mutant cells expressing LmjF07.0440
orLmjF07.0430wereproﬁcientforgrowthonglycerol,much
like the situation with the self-complemented strain, whereas
those mutant cells producing excess Cta1p could not grow
or divide on glycerol. Hence, LmjF07.0440 and LmjF07.0430
were adequate at substituting for Htd2p within the htd2Δ
mutant strain and are referred to hereafter as HTD2-1 and
HTD2-2, respectively. Unlike T. brucei, which contains only
a single 3-hydroxyacyl-ACP dehydratase HTD2, the related
species L. major contains two functional dehydratases, and
this ﬁnding is brieﬂy discussed.
3.2. Choosing LmjF27.2440 and LmjF24.2030 as Candidates
for Mitochondrial KAR1. The present study is addition-
ally concerned with identifying Leishmania KAR enzymes
with physiological 3-oxoacyl-ACP reductase activities. Three
candidate T. brucei KAR proteins have been described
previously [7], including TbKAR1; however, their phys-
iological function has hitherto not been chronicled. A
b l a s ts e a r c ho ft h eL. major database for proteins with
similarity to TbKAR1 revealed the existence of several
candidates with a signiﬁcant probability of representing
mitochondrial KAR1. The two top scorers, LmjF27.2440
(BlastP E-score 1.4e-73) and LmjF24.2030 (2.1e-05), are
SCglycerol
Htd2p
Cta1p
LmjF07.0440
LmjF07.0430
SD-Ura
Htd2p
Cta1p
LmjF07.0440
LmjF07.0430
Figure 2: Phenotype rescue of a yeast htd2Δ strain expressing
LmjF07.0440 or LmjF07.0430. Mutant S. cerevisiae BY4741htd2Δ
cellsproducingnativemitochondrialHtd2p,peroxisomalcatalaseA
Cta1p, or each of the mitochondrially targeted Leishmania proteins
LmjF07.0440 and LmjF07.0430 were grown on SD-Ura medium
selecting for plasmid presence, and following tenfold serial dilution
(triangle), the cells were applied to the indicated solid media.
already annotated in the database as putative 3-oxoacyl-
ACP reductases. As expected, both proteins were found to
be similar to their T. brucei counterpart (Figure 3)a n dt o
contain amino acid residues matching those in the catalytic
triad of bacterial FabG [33]. The probability that each of
the Leishmania proteins would represent a mitochondrial
enzyme was similarly estimated on the basis of the algo-
rithms used in the previous section, and the values were
compared to those obtained for TbKAR1: LmjF27.2440 (MP,
0.0909; PS, 11.1%; TP, 0.133), LmjF24.2030 (0.7445; 21.7%;
0.640), and TbKAR1 (0.8434; 13.0%; 0.732). These data
led to the assessment that LmjF27.2440 and LmjF24.2030
were potential KAR candidates, albeit the former protein,
LmjF27.2440, did not appear to be preceded by a recognis-
able MLS.
3.3. Expression of LmjF27.2440 Rescues the Respiratory Phe-
notype of oar1Δ Cells. To disclose the putative functions of
LmjF27.2440andLmjF24.2030as3-oxoacyl-ACPreductases,
the corresponding genes were similarly ligated behind the
CTA1 promoter. The low prediction values for LmjF27.2440
being a mitochondrial protein meant that a fungal MLSJournal of Biomedicine and Biotechnology 5
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LmjF24.2030:
TbKAR1       : :  22 
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LmjF24.2030: :  26 
LmjF24.2030:
TbKAR1       : :  88 
LmjF27.2440: : 140 
LmjF24.2030: : 100 
TbKAR1       :  : 156 
LmjF27.2440: : 208 
LmjF24.2030: : 173 
TbKAR1       :  : 230 
LmjF27.2440: : 282 
LmjF24.2030: : 244 
TbKAR1       : 
LmjF27.2440:
LmjF24.2030:
(Cont.)
Figure 3: Similarity of L. major LmjF24.2440 and LmjF24.2030 to their T. brucei homologue, TbKAR1. MitoProt predictions of cleaved
mitochondrial leader sequences are indicated (+). Catalytic amino acid residues occurring in E. coli FabG are marked (). The accession
number for TbKAR1 was AAX79999.
was appended to the N-terminus of each of the Leishmania
candidates. In the present case, yeast oar1Δ mutant cells
harbouring plasmids for expressing fungal Oar1p, Cta1p,
or mitochondrially targeted Leishmania LmjF27.2440 and
LmjF24.2030 were streaked on SCglycerol medium, and this
revealed that mutants expressing LmjF27.2440 or Oar1p
could grow on glycerol but not those with plasmids for
LmjF24.2030 or Cta1p (data not shown).
In a similar strategy to that used in the previous section,
the suﬃciency of Leishmania LmjF27.2440 at replacing yeast
Oar1p was demonstrated using serial dilutions that were
applied to SD-Ura or SCglycerol media. The results in
Figure 4 revealed that mutant cells expressing LmjF27.2440
were competent for growth on glycerol, to about one tenth
of the situation with the self-complemented strain, whereas
those mutant cells producing excess Cta1p could not grow or
divide on glycerol. Hence, the respiratory growth phenotype
of the oar1Δ mutant could be rescued, at least in part, by a
mitochondrially targeted LmjF27.2440.
3.4. The Electron Transfer Chain in oar1Δ Mitochondria is
Restored by LmjF27.2440. S. cerevisiae cells devoid of Oar1p
lack assembled cytochrome complexes [13], and so their
return to respiratory growth was presumed to coincide with
restored cytochrome complexes and a rehabilitated electron
transport chain. To demonstrate that the electron transfer
chain of mutant cells expressing LmjF27.2440 had been
regenerated, respiration competence was monitored with
an overlay consisting of 2,3,5-triphenyltetrazolium chloride
(TTC) that was applied to the aforementioned SD-Ura plate.
The results revealed that only mutant oar1Δ cells expressing
Oar1p or LmjF27.2440 could metabolise TTC to generate
the red colour, whereas high concentrations of oar1Δ cells
expressing Cta1p remained white (lower panel; Figure 4).
This indicated that within the LmjF27.2440-expressing
mutant, at least a partial recovery of the mitochondrial
electron transfer chain had been achieved.
3.5. Expression of LmjF27.2440 Resumes Lipoic Acid Produc-
tion in the oar1Δ Mutant. As mentioned in the introduction,
trypanosome FASII is involved in the synthesis of the
octanoate precursor of lipoic acid [7]. Hence, to couple the
expression of LmjF27.2440 with lipoic acid biosynthesis in
yeast mitochondria, a biological assay relying on mutant
bacterial cells was employed to measure the levels of lipoic
acid in the previous three strains (each grown in triplicates).
The results showed that extracts produced from the negative
control yeast strain (oar1Δ cells expressing Cta1p) gave rise
to a growth level of these lipoic-acid deﬁcient bacterial cells
that was equivalent to 23.3 ± 2.8ng lipoic acid per gram wet
weight yeast cells (values are mean ± S.D., n = 3), whereas
the lipoic acid present in mutant yeast cells expressing fun-
gal Oar1p or Leishmania LmjF27.2440 promoted bacterial
growth to levels corresponding to 294.3 ± 54.5 and 59.0 ±
15.4ng lipoic acid per gram wet weight, respectively. The
combined results for LmjF27.2440, referred to hereafter as
LmKAR1, were commensurate with the functions of a FASII-
like 3-oxoacyl-ACP reductase, and the implications of this
ﬁnding are discussed.6 Journal of Biomedicine and Biotechnology
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Figure 4: Phenotype rescue of a yeast oar1Δ strain express-
ing LmjF27.2440. S. cerevisiae BY4741oar1Δ mutants producing
native mitochondrial Oar1p, Cta1p, or mitochondrially targeted
LmjF27.2440 were propagated on SD-Ura medium that applied
selective pressure for plasmid maintenance, and following sequen-
tial tenfold dilution (triangle), the cells were spotted onto the
indicated solid media. Respiration competence was examined by
applying 2,3,5-triphenyltetrazolium chloride (TTC) as an overlay
to the SD-Ura medium.
4. Discussion
Although several components of T. brucei FASII have been
revealed before, TrypanosomaandLeishmaniaaresuﬃciently
diﬀerent to warrant a study dedicated to identifying FASII
also in L. major. In the present work, two novel L. major
proteins, LmjF07.0440 (HTD2-1) and LmjF07.0430 (HTD2-
2), were shown to rescue the mutant phenotype of S.
cerevisiae htd2Δ cells with respect to respiratory growth,
thereby acting as physiologically functional 3-hydroxacyl-
ACPdehydratases.Theuseofyeasthtd2Δcellsforidentifying
Trypanosomatidae HTD2 has been established previously
[9],aﬃrmingthatfunctionalcomplementationstudiesentail
a major experimental advantage over more conventional
methods for characterising enzymatic activities. In the
aforementioned case of TbHTD2, diﬃculties in measur-
ing enzyme activities could only be overcome by using
a bacterially expressed fusion protein [9]. In order to
obviate the lengthy and laborious task of generating soluble
Leishmania proteins, complementation of the fungal HTD2
gene was used here instead, and this method provided a very
eﬀective alternative for demonstrating the mitochondrial
dehydratase function of LmHTD2-1 and LmHTD2-2. Unlike
the situation with T. brucei, the observation that L. major
contains two HTD2 genes is surprising. However, since
there are no data presently available in the Leishmania
databases regarding the potential expression of the two genes
at diﬀerent life-cycle stages, the selective advantage behind
this gene duplication remains enigmatic.
A further important result to emerge here was the
identiﬁcation of LmjF27.2440 as a physiologically functional
3-oxoacyl-ACP reductase LmKAR1, potentially of mito-
chondrial FASII. In T. brucei, three diﬀerent proteins have
been chronicled as representing this enzyme, and although
they were all experimentally shown to be directed to the
parasite’s mitochondria [7], no data were presented for
their enzyme activities or physiological functions. Here, the
ability of LmjF27.2440 to replace Oar1p in oar1Δ mutant
cells was determined, albeit the extent of the phenotype
rescue achieved by ectopically producing LmjF27.2440 was
limited. Judging from the diﬀerence in respiratory growth
of the LmKAR1-rescued mutants compared with the self-
complemented strain (upper panel; Figure 4), it can be
surmised that the former strain grew to a level that was
approximately ﬁve- to tenfold less than the latter. The
reduced respiratory growth seen here was additionally
mirrored by a comparatively lower eﬃciency at metabolising
TTC (lower panel; Figure 4). Moreover, a ﬁvefold diﬀerence
in levels of lipoic acid production could also be discerned
between the two strains. The reason for this apparent
discrepancy remains unclear, since by using an identical
approach with the htd2Δ mutant, its phenotype could be
rescued by LmHTD2-1 or LmHTD2-2 essentially to the level
achieved by native Htd2p. One possible explanation leans on
the eﬃcacy of mitochondrial targeting.
The poor predictability regarding the potential mito-
chondrial targeting of LmjF27.2440 prompted the addition
of a fungal MLS to the N-terminus of the protein. In this
respect it should be noted that although the process of
importing proteins into the mitochondria is well conserved
across eukaryotes, some diﬀerences do exist, especially
between yeast and mammals [34]. Since an exhaustive
discourse on these diﬀerences is beyond the scope of this
discussion, it can at least be speculated that in the situation
of a lack of a formal MLS, LmjF27.2440 might actually
containacrypticsignalforcompartmentalisation(beginning
with the amino acid residue at position 53; Figure 3), which
may or may not be recognised by yeast. The potentially
deleterious eﬀect of adding a fungal MLS on top of such
a cryptic signal cannot be presently assessed. While the
ultimate conﬁrmation for mitochondrial localisation of
LmKAR1, but also LmHTD2-1 and LmHTD2-2, will require
dedicated studies on Leishmania using speciﬁc antibodies or
GFP fusion proteins, within the context of yeast it is notJournal of Biomedicine and Biotechnology 7
uncommon to submit to the temptation of ensuring that
heterologous mitochondrial proteins be correctly targeted
by artiﬁcially appending an additional fungal MLS [14].
Nevertheless, when considering the situation in T. brucei,
whereby the KAR1 [7] and HTD2 [9] proteins have been
convincingly localised to the mitochondria, it is tempting to
speculate that the analogous L. major components will also
be similarly compartmentalised.
In reference to the number of KAR enzymes present in
FASIIofLeishmania,thesecondproteintested,LmjF24.2030,
which was predicted to be a mitochondrial protein, never-
theless, failed to rescue the mutant phenotype. In the context
of a yeast system, this observation alone is not suﬃcient to
discount completely the possibility that LmjF24.2030 might
still represent a functional KAR in Leishmania.H o w e v e r ,i t
was no longer attractive to pursue LmjF24.2030 any further
once it failed to rescue the yeast mutant phenotype, since
it was conspicuously less similar to TbKAR1 compared
with LmjF27.2440 (Figure 3). To conclude, the present
identiﬁcation of three probable FASII components in L.
major will enrich our knowledge of the molecular biology of
an organism threatening the health of hundreds of millions
of people worldwide and may help expose its mitochondrial
FASII system to novel drug design.
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